Correlations between methylenetetrahydrofolate reductase gene polymorphisms and venous thromboembolism: A meta-analysis of 99 genetic association studies

Abstract

We performed this meta-analysis to better assess the relationship between methylenetetrahydrofolate reductase gene (MTHFR) polymorphisms and the risk of venous thromboembolism. Eligible studies were searched in PubMed, Medline, Embase, and Web of Science. Odds ratios with 95% confidence intervals were used to assess associations of MTHFR polymorphisms with venous thromboembolism. A total of 99 genetic association studies were enrolled for analyses. Although no positive results were detected in overall analyses for the rs1801131 polymorphism. Further subgroup analyses according to ethnicity of participants and type of disease revealed that the rs1801131 polymorphism was significantly correlated with the risk of pulmonary embolism. For the rs1801133 polymorphism, significant association with the risk of venous thromboembolism was found in the dominant, recessive, and allele models. Further subgroup analyses according to ethnicity of participants revealed that the rs1801133 polymorphism was significantly associated with the risk of venous thromboembolism in Caucasians, East Asians, and West Asians. When we stratified available data according to type of disease, we found that the rs1801133 polymorphism was also significantly correlated with the risk of deep vein thrombosis and pulmonary embolism. In conclusion, our findings indicate that the MTHFR rs1801133 polymorphism may serve as a potential biological marker for venous thromboembolism in Caucasians, East Asians, and West Asians. Moreover, the MTHFR rs1801133 polymorphism may be implicated in the development of deep vein thrombosis and pulmonary embolism, while the MTHFR rs1801131 polymorphism may contribute to the development of pulmonary embolism.

Keywords

Methylenetetrahydrofolate reductase gene polymorphism venous thromboembolism meta-analysis

Get full access to this article

View all access options for this article.

References

Wilbur

Shian

. Diagnosis of deep venous thrombosis and pulmonary embolism. Am Fam Physician 2012; 86: 913–919.

Naess

Christiansen

Romundstad

et al.

Incidence and mortality of venous thrombosis: A population-based study. J Thromb Haemost 2007; 5: 692–699.

Silverstein

Heit

Mohr

et al.

Trends in the incidence of deep vein thrombosis and pulmonary embolism: A 25-year population-based study. Arch Intern Med 1998; 158: 585–593.

Heit

Silverstein

Mohr

et al.

factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study. Arch Intern Med 2000; 160: 809–815.

Streiff

. Predicting the risk of recurrent venous thromboembolism (VTE). J Thromb Thrombolysis 2015; 39: 353–366.

Moll

Varga

. Homocysteine and MTHFR mutations. Circulation 2015; 132: e6–e9.

Rozen

. Genetic predisposition to hyperhomocysteinemia: Deficiency of methylenetetrahydrofolate reductase (MTHFR). Thromb Haemost 1997; 78: 523–526.

Santilli

Davì

Patrono

. Homocysteine, methylenetetrahydrofolate reductase, folate status and atherothrombosis: A mechanistic and clinical perspective. Vascul Pharmacol 2016; 78: 1–9.

Basol

Karakus

Savas

et al.

The importance of MTHFR C677T/A1298C combined polymorphisms in pulmonary embolism in Turkish population. Medicina (Kaunas) 2016; 52: 35–40.

10.

Bharatkumar

Nagaraja

Christopher

. Hyperhomocysteinemia and methylenetetrahydrofolate reductase C677T polymorphism in cerebral veno-sinus thrombosis. Clin Appl Thromb Hemost 2014; 20: 78–83.

11.

Ghaznavi

Soheili

Samiei

et al.

Association of methylenetetrahydrofolate reductase C677T polymorphism with hyperhomocysteinemia and deep vein thrombosis in the Iranian population. Vasc Specialist Int 2015; 31: 109–114.

12.

Kupeli

Verdi

Simsek

et al.

Genetic mutations in Turkish population with pulmonary embolism and deep venous thrombosis. Clin Appl Thromb Hemost 2011; 17: E87–E94.

13.

Moher

Liberati

Tetzlaff

et al.

PRISMA group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med 2009; 151: 264–269.

14.

Stang

. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603–605.

15.

Trimmer

. Methylenetetrahydrofolate reductase: Biochemical characterization and medical significance. Curr Pharm Des 2013; 19: 2574–2593.

16.

Dai

Zheng

et al.

Homocysteine metabolism gene polymorphisms (MTHFR C677T, MTHFR A1298C, MTR A2756G and MTRR A66G) jointly elevate the risk of folate deficiency. Nutrients 2015; 7: 6670–6687.

17.

Alhenc-Gelas

Arnaud

Nicaud

et al.

Venous thromboembolic disease and the prothrombin, methylene tetrahydrofolate reductase and factor V genes. Thromb Haemost 1999; 81: 506–510.

18.

de Franchis

Fermo

Mazzola

et al.

Contribution of the cystathionine beta-synthase gene (844ins68) polymorphism to the risk of early-onset venous and arterial occlusive disease and of fasting hyperhomocysteinemia. Thromb Haemost 2000; 84: 576–582.

19.

Gemmati

Previati

Serino

et al.

Low folate levels and thermolabile methylenetetrahydrofolate reductase as primary determinant of mild hyperhomocystinemia in normal and thromboembolic subjects. Arterioscler Thromb Vasc Biol 1999; 19: 1761–1767.

20.

Hainaut

Jaumotte

Verhelst

et al.

Hyperhomocysteinemia and venous thromboembolism: A risk factor more prevalent in the elderly and in idiopathic cases. Thromb Res 2002; 106: 121–125.

21.

Keijzer

den Heijer

Blom

et al.

Interaction between hyperhomocysteinemia, mutated methylenetetrahydrofolatereductase (MTHFR) and inherited thrombophilic factors in recurrent venous thrombosis. Thromb Haemost 2002; 88: 723–728.

22.

Zappacosta

Graziano

Persichilli

et al.

5,10-Methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms: Genotype frequency and association with homocysteine and folate levels in middle-southern Italian adults. Cell Biochem Funct 2014; 32: 1–4.

23.

Xuan

Tian

et al.

Levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, and risk of coronary artery disease: A meta-analysis based on 4713 participants. Eur J Prev Cardiol 2016; 23: 502–510.

24.

Rubba

Gentile

Marotta

et al.

Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia. Eur J Prev Cardiol 2017; 24: 1051–1059.